Abstract: Inflammatory bowel diseases (IBDs) are disorders characterized by chronic inflammation of the intestinal tract.
The focus of the present study was to examine the effect of the fungus Coriolus versicolor (CV), underlining its correlation with Toll-like receptors 4 (TLR4) and nuclear factor erythroid 2-related factor 2 (Nrf2); we aim to evaluate its anti-inflammatory and antioxidant effect in mice exposed to experimental colitis. The model was induced in mice by colon instillation of dinitrobenzenesulfonic acid (DNBS), CV was administered orally (200 mg per kg) daily for 4 days. On day 4, the animals were killed, and the tissues collected for histological, biochemical, and molecular analyses. Four days after DNBS administration, CC motif chemokine ligand 2 (CCL2), prostaglandin E2 (PGE2), interleukin-1 (IL-1 ), and tumor necrosis factor- (TNF- ) production increased in association with damage to the colon.
Neutrophil infiltration, as assessed by myeloperoxidase (MPO) activity, in the mucosa was associated with overexpression of P-selectin and intercellular adhesion molecule 1 (ICAM1). Immunohistochemistry for nitrotyrosine and poly-(ADP-Ribose)-polymerase (PARP) showed evident stain in the inflamed colon. Treatment with CV significantly reduced the appearance of colon changes and weight loss. These effects were associated with a remarkable ability of CV to reduce the expression of TLR4 and modulate the pathway of nuclear factor kappa-light-chainenhancer of activated B cells (NF-kB). This improved the colon architecture, reduced MPO activity, the release of proinflammatory cytokines, the presence of nitrotyrosine, and the hyperactivation of PARP, as well as the up-regulation of P-selectin and ICAM1. Furthermore, we studied the action of CV on the Nrf2/HO-1 pathway, which is important for maintaining redox balance, demonstrating that CV by significantly increasing both enzymes is able to counteract the oxidative stress induced by DNBS.
Taken together, our results clearly show that this natural compound can be considered as a possible dietary supplement against colitis.
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Impact of Gastrointestinal Tract on Mushroom Biomass: Deciphering Their Potential on Gut Microbiota Modulation.
Helena Araújo-Rodrigues, Ana Sofia Salsinha, João Bettencourt Relvas, Freni K. Tavaria, Manuela E. Pintado Presented at the the 10th International Human Microbiome Consortium (IHMC) Congress held on June 22-25, 2024 in Rome Italy. -
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential.
Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo, Anna Signorile, Luigi Maiolino, Salvatore Cuzzocrea, and Vittorio Calabrese.
Curr Neuropharmacol 2023 Dec 8. PMID: 38073105
-
Mushrooms as Functional Foods for Ménière’s Disease.
Victoria Bell and Tito Horácio Fernandes.
Appl. Sci. 2023, 13, 12348. -
Antioxidants, Hormetic Nutrition, and Autism.
Modafferi Sergio, Lupo Gabriella, Tomasello Mario, Rampulla Francesco, Ontario Marialaura,
Scuto Maria, Trovato Salinaro Angela, Arcidiacono Antonio, Anfuso Carmelina Daniela,
Legmouz Maria, Azzaoui Fatima-Zahra, Palmeri Agostino, Spano’ Sestina, Biamonte Francesca,
Cammilleri Gaetano, Fritsch Tilman, Sidenkova Alena, Calabrese Edward, Wenzel Uwe and Calabrese Vittorio. Curr Neuropharmacol. 2023 Aug 17.